CTOs on the Move

Intrexon

www.actogenix.com

 
Intrexon Corporation (NYSE: XON) is a leader in synthetic biology focused on collaborating with companies in Health, Food, Energy, Environment, and Consumer Sectors to create biologically-based products that improve the quality of life and the health of the planet. Through the company’s proprietary UltraVector® platform and and suite of technologies, Intrexon provides its partners with industrial-scale design and development of complex biological systems. The UltraVector® platform delivers unprecedented control over the quality, function, and performance of living cells. We call our synthetic biology approach and integrated technologies Better DNA®, and we invite you to discover more at www.DNA.com.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.actogenix.com
  • 20358 Seneca Meadows Pkwy
    Germantown, MD USA 20876
  • Phone: 301.556.9900

Executives

Name Title Contact Details

Funding

Intrexon raised $200M on 08/22/2015

Similar Companies

Southern Plaza Retirement Comm

Southern Plaza Retirement Comm is a Bethany, OK-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Apotex Pharma Chem

Apotex Pharma Chem is a Brantford, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Shaw Science Partners

Shaw Science Partners is a Atlanta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Medisca Pharmaceutique Inc

Medisca Pharmaceutique Inc is a Saint-Laurent, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Daktari Diagnostics

Daktari Diagnostics is a healthcare solutions company that enables enhanced disease management in both developed and developing countries. Our portable point-of-care diagnostic platform, with built-in wireless connectivity and an intuitive cloud-based data management system, provides the real-time information necessary to improve clinical outcomes for individual patients and support global disease elimination programs. Daktari`s initial products will target viruses of worldwide significance, including Hepatitis C and HIV. The company recently announced a Hepatitis C partnership with Merck & Co (MSD).